Acendis Pharma Announces Third Quarter 2016 Financial Results

Acendis Pharma (NASDAQ:ASND) today announces its financial results for the third quarter of 2016, which ended on September 30.
According to the press release:

“For the third quarter of 2016, Ascendis Pharma reported a net loss of €18.3 million, or €0.72 per share (basic and diluted) compared to a net loss of €7.3 million, or €0.30 per share (basic and diluted) during the same period in 2015.”

CEO Jan Mikkelsen said the following:

The third quarter was productive and successful as we outlined our Vision 20/20 strategic roadmap, initiated the TransCon Growth Hormone Phase 3 heiGHt Trial, and announced two additional pipeline programs, TransCon Parathyroid Hormone (PTH) and TransCon C-Type Natriuretic Peptide (CNP).

Read the full press release here.